Wade’s CV impact, a digital stethoscope for HFrEF, and more. Every month, Section Editor L.A. McKeown curates a roundup of ...

Overall, there was a “modest” decline in use of embolic protection in the year after the PROTECTED TAVR results were released ...

Out-of-hospital mortality before 30 days was 1.2%, with roughly two-thirds of these patients dying from cardiovascular causes.

Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...

With about 7% of CVD in the country attributable to high temperatures, experts say tools to adapt are urgently needed.

Payment will be provided when TTVR is delivered for an FDA-approved indication in the context of a CMS-approved study.

A risk-assessment tool incorporating NT-proBNP and high-sensitivity troponin performs better than clinical scores for ...

In this “data-scarce zone,” the paper offers a road map for the first 24 hours and tips for transfer, teams, and more.

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Clinicians should be asking patients about cannabis use, particularly if there are cardiovascular concerns, say researchers.

Patients can now easily buy these tests, but cardiologists must consider their quality when using the information to guide ...

The US data also point to lower costs and shorter stays at these expert centers, an argument for regionalized care akin to ...